MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Group announced that the U.S. Food and Drug Administration, FDA, has accepted the Biologics License Application, BLA, for RP1 ...

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

Shoals Technologies Group, Inc. offers a top risk-reward profile in the solar sector with creative solutions and good ...

Lionel Messi's father Jorge Messi once reponded to backlash over his son winning the Ballon d'Or ahead of Cristiano Ronaldo.

In 2024, additional refinements were made towards finalizing the manufacturing of GP2, the reconstitution of GLSI-100 in the pharmacy, and the injection of GLSI-100 in the clinic. As a result, the ...

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...

Replimune Group Inc (NASDAQ: NASDAQ:REPL), a biotech firm focused on oncolytic immunotherapies, announced today that its Biologics License Application (BLA) for RP1 in combination with nivolumab has ...